@article{77d796340fb8449ea45fb299a8540efc,
title = "The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation",
abstract = "Introduction: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.",
keywords = "Consensus guidelines, Mesothelioma, Radiation therapy, Treatment recommendations",
author = "Gomez, {Daniel R.} and Andreas Rimner and Simone, {Charles B.} and Cho, {B. C.John} and {de Perrot}, Marc and Adjei, {Alex A.} and Raphael Bueno and Gill, {Ritu R.} and Harpole, {David H.} and Mary Hesdorffer and Hirsch, {Fred R.} and Jackson, {Andrew A.} and Pass, {Harvey I.} and Rice, {David C.} and Rusch, {Valerie W.} and Tsao, {Anne S.} and Ellen Yorke and Kenneth Rosenzweig",
note = "Funding Information: This research was funded in part by Cancer Center Support (Core) grant CA016672 from the National Cancer Institute , National Institutes of Health, to The University of Texas M. D. Anderson Cancer Center and through National Institutes of Health / National Cancer Institute Cancer Center Support Grant P30 CA008748 (to Dr. Yorke). Funding Information: Disclosure: Dr. Hirsch is coinventor of a University of Colorado–owned patent titled “EGFR IHC and FISH as Predictive Biomarkers for EGFR Therapy”; in addition, Dr. Hirsch has participated in advisory boards for BMS, Genentech/Roche, HTG, Lilly, Merck, Pfizer, and Ventana, and Dr. Hirsch's laboratory has received research grants (through the University of Colorado) from Genentech, BMS, Lilly, Bayer, and Clovis. Dr. Rimner reports grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and AstraZeneca and personal fees from AstraZeneca, Bristol-Myers Squibb, and Merck outside the submitted work. Dr. Gomez has participated in advisory boards for AstraZeneca. He has received research funding from Merck, AstraZeneca, BMS, and Varian. He has received personal fees from Varian, Merck, AstraZeneca, BMS, Reflexion, OncLive, and US Oncology outside of the submitted work. Dr. Bueno reports grants from Roche Genentech, Merck Oncology, and Novartis outside the submitted work. Dr. Tsao reports personal fees and research support from BMS, Genentech, Ariad, Merck, AstraZeneca, Boehringer-Ingelheim, and Takeda; personal fees from Roche, Novartis, EMD Serono, Epizyme, and Huron; grants, personal fees, and research support from Eli Lilly; and research support from Seattle Genetics, Polaris, and Millenium outside the submitted work. Dr. de Perrot reports personal fees from Bayer and Actelion outside the submitted work. Dr. Rusch reports travel support from Bristol-Myers Squibb and payment for a meeting and preparation for a clinical trial review from the NIH/Coordinating Center for Clinical Trials during the conduct of the study, as well as grants from Genelux and Genentech and travel support for teaching sessions from Intuitive Surgical outside the submitted work. The remaining authors declare no conflict of interest.This research was funded in part by Cancer Center Support(Core) grant CA016672 from the National Cancer Institute, National Institutes of Health, to The University of Texas M. D. Anderson Cancer Center and through National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748 (to Dr. Yorke). Disclosure: Dr. Hirsch is coinventor of a University of Colorado–owned patent titled “EGFR IHC and FISH as Predictive Biomarkers for EGFR Therapy”; in addition, Dr. Hirsch has participated in advisory boards for BMS, Genentech/Roche, HTG, Lilly, Merck, Pfizer, and Ventana, and Dr. Hirsch's laboratory has received research grants (through the University of Colorado) from Genentech, BMS, Lilly, Bayer, and Clovis. Dr. Rimner reports grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and AstraZeneca and personal fees from AstraZeneca, Bristol-Myers Squibb, and Merck outside the submitted work. Dr. Gomez has participated in advisory boards for AstraZeneca. He has received research funding from Merck, AstraZeneca, BMS, and Varian. He has received personal fees from Varian, Merck, AstraZeneca, BMS, Reflexion, OncLive, and US Oncology outside of the submitted work. Dr. Bueno reports grants from Roche Genentech, Merck Oncology, and Novartis outside the submitted work. Dr. Tsao reports personal fees and research support from BMS, Genentech, Ariad, Merck, AstraZeneca, Boehringer-Ingelheim, and Takeda; personal fees from Roche, Novartis, EMD Serono, Epizyme, and Huron; grants, personal fees, and research support from Eli Lilly; and research support from Seattle Genetics, Polaris, and Millenium outside the submitted work. Dr. de Perrot reports personal fees from Bayer and Actelion outside the submitted work. Dr. Rusch reports travel support from Bristol-Myers Squibb and payment for a meeting and preparation for a clinical trial review from the NIH/Coordinating Center for Clinical Trials during the conduct of the study, as well as grants from Genelux and Genentech and travel support for teaching sessions from Intuitive Surgical outside the submitted work. The remaining authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2019 International Association for the Study of Lung Cancer",
year = "2019",
month = jul,
doi = "10.1016/j.jtho.2019.03.030",
language = "English (US)",
volume = "14",
pages = "1172--1183",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",
}